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Angiogenesis, an essential component of tumor growth and survival, is regulated by complex interactions between several cell
types and soluble mediators. Heterogeneous tumor vasculature originates from the collective eﬀect of the nature of carcinoma and
the complexity of the angiogenic network. Although the application of angiogenesis inhibitors in some types of cancers has shown
clinical beneﬁts, predictive markers to assess treatment eﬀects have yet to be established. In this review, we focus on tumor vessel
maturity as a potential marker for evaluating treatment response.
1.Introduction
Like normal tissues, malignant tissues are dependent on
an adequate blood supply. Unlike normal tissues, however,
angiogenesis is reactivated under pathological conditions,
such as wound healing and malignancies [1]. Inﬂammation,
metabolic stress and hypoxia are three major conditions
involved in angiogenesis [2]. As malignant cells grow, the
“demand” for nutrients and oxygen necessitates new “sup-
ply” routes, that is, new blood vessels. Early studies in this
ﬁeld have revealed that a tumor mass cannot exceed 1mm3
without angiogenesis [3]. Although endothelial cells (ECs)
are typically quiescent in humans [4], they can proliferate
once the angiogenic switch turns on. This switch is oﬀ
or diﬀerentially regulated in normal tissues based on the
equilibrium between positive and negative angiogenic regu-
lators. Upon receiving dominant proangiogenic stimuli from
malignant cells or the tumor microenvironment through
several eﬀectors, such as vascular endothelial growth factors
(VEGFs), platelet-derived growth factor (PDGF), placenta-
derived growth factor (PlGF), hypoxia-inducible factor-
1 (HIF-1α), angiopoietin-2, transforming growth factor β
(TGF-β), or interleukin-8, ECs from preexisting vessels
become activated. Activated ECs modify their interaction
with perivascular cells (pericytes, PCs) and release pro-
teases to degrade the surrounding basement membrane
and extracellular matrix to facilitate EC proliferation and
sprouting into the matrix [5]. Endothelial precursor cells
(EPCs) from bone marrow also integrate with these growing
vessels [6].
2.Tumor Vessel Maturity
Sprouting microvessels establish a plexus that keeps all
tumor cells within a distance of 100–200μm from the
blood supply [7]. This new architecture is considered
“immature” and diﬀe r sf r o mn o r m a l( o rm a t u r e )v a s c u l a r
structures in many ways. Immature vessels lack vascular
organization and hierarchy and are unevenly distributed in
tumor tissue. They are usually irregularly shaped, tortuous
and dilated. As a result of impaired cell-to-cell attachment,
abnormalbasementmembranes,andincreasedpermeability,
the new microvessels are leaky and cannot sustain balanced
intravascularpressuregradients,whichcanleadtointerstitial
hypertension. ECs in the tumor vasculature are dependent
oncellsurvivalfactors(e.g.,VEGF)forsurvivalincontrastto
E C si nn o r m a lt i s s u e s[ 8]. Pericytes, which stabilize ECs and
mediate EC survival and maturation in normal vasculature
both through direct cell contact with ECs and paracrine
signaling, are also abnormal in the tumor vasculature [9].
Pericytes are usually absent in the tumor vasculature or2 Journal of Oncology
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Figure 1: Hypoxia inducible factors (HIFs) and their role in endothelial cell proliferation. HIF-1α is hydroxylated by prolyl hydroxylase
domain proteins (PHDs) and degraded in proteasomes under oxygenated conditions. When the oxygen level decreases, PHD activity is
reduced, which leads to the accumulation of HIF-1α. Upon formation, the HIF-1α/β complex activates the transcription of numerous genes.
Hypoxia and HIF-1α enhance the expression of VEGFR2, which induces DLL4 expression in the tip cell. Furthermore, DLL4 interacts with
the Notch intracellular domain and increases its activity, which increases endothelial cell proliferation. Upregulation of HIF-2α due to lower
degradation activates the junctional protein vascular endothelial cadherin (VE cadherin). VE cadherin induces a normalized endothelial
phenotype by inhibiting VEGF-driven proliferation and upregulating the soluble isoform of the VEGF-trap VEGFR1 [12].
have loose associations with ECs, leaving most of the tumor
microvessels immature. The basement membrane is rich in
collagen type IV and a source of growth factors for ECs
and PCs in normal vessels. In tumor vessels, the basement
membrane has defects in its structure and composition
and can provide a productive environment for metastatic
malignant epithelial cells and proliferating ECs [10].
ECs are proliferative in a diverse manner based on
immunostainingforproliferationmoleculesincancertissues
[11].
During tumor growth, the tumor vasculature develops
as the angiogenic switch is intermittently turned on and oﬀ
[12]. The imbalance between tumor cell growth and vascular
formation may often cause a collapse of tumor cells and
the new vasculature. Hypoxic areas exist heterogeneously in
the majority of human solid cancer tissues [13]. HIFs are a
family of transcription factors that are activated in response
to hypoxic tumor tissue in diﬀerent ways (Figure 1).
3. AngiogenesisinHumanCancer
Breastcanceristhemostcommoncanceramongwomenand
isstudiedasanangiogeniccarcinomaduetothehighexpres-
sion levels of proangiogenic factors, such as VEGFs, HIF-
1α,T G F - β, or thymidine phosphorylase (TP), in carcinoma
cells [14]. Various components of the angiogenic pathway
have been studied as prognostic and predictive factors in
breast cancer. Distinct patterns of vascularity (using an
EC marker) in ductal carcinoma in situ (DCIS) might be
useful to identify patients who are at risk of relapse [15].
Bone marrow metastasis as a direct result of interactions
between carcinoma cells and the vascular network has been
shown to have a higher prevalence in breast cancer patients
with high-grade vascular tumors [16]. Angiogenesis has
been used to predict the likelihood of tumor response to
adjuvant chemotherapy or hormone therapy. Heterogeneous
characteristics of biological markers, such as estrogen and
p r o g e s t e r o n er e c e p t o r s( E Ra n dP g R ,r e s p . )a sw e l la sh u m a n
epidermal growth factor receptor-2 (HER-2), deﬁne the
clinical outcome of breast cancer patients. Patients with
ER-positive tumors have been shown to have prolonged
disease-free survival and an increased likelihood of tumor
response to endocrine therapies [17]. After the introduc-
tion of trastuzumab, a humanized monoclonal antibody
directed against the extracellular domain of ErbB [18],
HER-2-targeted therapies has changed the disease course of
originally aggressive type of HER-2-positive breast cancer
[19]. Triple-negative breast cancer (ER-, PgR-, and HER-
2-negative; TNBC) comprises a heterogeneous subgroup of
tumors characterized by an aggressive clinical course and
poor survival and is not amenable to hormone therapy or
HER2-directed agents [20].
Breast cancer is classiﬁed into distinct molecular sub-
types based on expression proﬁling using DNA microarrays
[21]. These subtypes are luminal A, luminal B, (HER2)-
overexpressing, normal breast tissue-like, basal-like and the
more recently identiﬁed subtype claudin-low [22]. These
subtypes respond diﬀerently to therapy and are associated
with diﬀerent outcomes. The shortest survival times have
been observed in patients with the basal-like and HER2-
overexpressing subtypes [23]. Highly proliferative tumors,
including those that are negative for the estrogen, proges-
terone, and HER2/neu receptors, have enhanced angiogen-
esis, which supports rapid growth and early metastases and
h a v eb e e nf o u n dt oh a v eh i g hl e v e l so fV E G F[ 24]. Many of
the molecules involved in neovascularization pathways have
become targets for antiangiogenic drugs, which are under
evaluation in clinical trials or are currently administered
in clinics [25]. Although many of these therapies, such asJournal of Oncology 3
bevacizumab (anti-VEGF-A), are being used in combination
withothertherapeuticmodalities,suchaschemotherapyand
endocrine therapy [26], studies are ongoing to ﬁnd the opti-
mal method to elucidate tumor response and overcome ther-
apeutic resistance to antiangiogenic treatments. Genomic
activation of VEGF-A is higher in TNBCs compared to other
subgroups of breast cancer and suggests a speciﬁc role for
bevacizumab treatment in this subgroup [27].
Although several distinguishing molecular features have
been characterized in basal-like cancer cells, the microenvi-
ronmental features of this type of cancer have not been well
characterized. A recent study on cocultures of breast cancer
cell lines with ﬁbroblasts has identiﬁed stromal interactions
that distinguish basal-like from luminal-type breast cancers
[28].
Inarecentstudyon1788primaryinvasivebreastcancers,
VEGF expression is correlated with intrinsic subtypes with
a higher frequency in luminal-type B, HER2, and basal-
like types but not luminal-type A [24]. In another study
of 564 tissue microarrays from primary tumors from pre-
menopausal breast cancer patients who had been random-
izedtoadjuvanttamoxifenornoadjuvanttreatment,TNBCs
show increased protein expression of epithelial growth factor
receptor (EGFR) and VEGFR2, whereas the expression of
VEGF-A is not a speciﬁc biomarker of TNBCs [27].
A pathological examination using CD34 of one thousand
early-stage primary breast cancer specimens has shown
that basal-like breast cancer and TNBCs had signiﬁcantly
higher microvessel densities (MVDs) than the nonbasal
and non-TNBC groups [29]. In basal-like breast cancers,
high MVD was associated with a larger tumor size and a
higher grade. However, this association is not apparent in
the TNBC group. CD34 has been reported to be present
on endothelial progenitors [30]. Despite the fact that other
morphological characteristics of the tumor vasculature are
not available for evaluation, higher CD34-positive vascular
structures might show a trend for the presence of immature
vessels in basal-like breast cancers and TNBCs in this study.
In addition, investigators have shown that in TNBCs and
basal-like breast cancers, vascular invasion almost entirely
consists of lymphatic vessels. Basal-like breast cancers have
been reported to preferably metastasize to the brain and
liver [31] and have been interpreted as distinct blood-
borne metastases. However, the results from the afore-
mentioned study might be explained by other molecular
featuresoftheinteractionsbetweenbasal-likemalignantcells
and endothelial cells.
In an in vitro study on breast cancer cell lines with
diﬀerent expression levels of ERα, Ang-1 mRNA and protein
levels are higher in MDA-MB-231 cells (ERα-negative cell
line)comparedtothoseofMCF-7cells,S30cells,andHMEC
(all ERα-positive cell lines) [32]. E2 treatment signiﬁcantly
attenuates Ang-1 mRNA and protein expression levels in S30
cells. Ang-1, VEGF, and CD31 staining in tumor samples
from animals that have been inoculated with S30 and MDA-
MB-231 cells reconﬁrms decreased angiogenesis in vivo in
tumors that originated from the ERα-positive cell line.
Circulating tumor cells (CTCs) and disseminated tumor
cells (DTCs) have a signiﬁcant prognostic role in breast
cancer patients [33]. These cells have heterogeneous bio-
logical characteristics that promote metastasis. In addition
to the proangiogenic role of VEGF, VEGF stimulates tumor
cell proliferation [34]. In a study of CTCs obtained from
breast cancer patients, VEGF and its upstream regulators
HIF-1 and phosphorylated-focal adhesion kinase (pFAK)
are expressed in 73%, 56%, and 81% of detected CTCs,
respectively [35]. Although the biological signiﬁcance of
these ﬁndings remains unknown, they implicate a possible
role for angiogenic characteristics in the metastatic behavior
of CTCs.
A genomic study on 134 primary breast cancers and
27 regional or distant metastases showed a high expression
of a 13-gene cluster (VEGF proﬁle) containing VEGF,
angiopoetin-like 4 (ANGPTL4), and adrenomedullin (ADM)
in tumors from patients with conﬁrmed distant disease
at the time of diagnosis (i.e., MetScore = 3) [36]. VEGF
and ANGPTL4 are endothelial cell growth inducers, and
ADM is an inducer of lymphatic vessel growth [37, 38]. In
addition, “perinecrotic” HIF-1α IHC staining correlates with
the expression of the VEGF proﬁle. Eight of these 13 genes
had hypoxia response elements that are 2000bp upstream of
their start codons. The VEGF proﬁle also correlates with the
expression proﬁle of three individual genes (Snail, Twist, and
HIF-1α) and the intrinsic subtype of breast cancer.
BRCA-associated breast cancers are diﬀerent from spon-
taneous breast cancers in many aspects, such as morphology,
triple negativity, basal cytokeratin expression, and p53
mutations [39]. HIF-1α overexpression is more frequent in
BRCA1-related breast cancer compared to that in sporadic
cancer in a small series of 30 cases [40]. Elevated expression
of HIF-1α and the loss of prolyl hydroxylase enzyme 3
(PHD3) and factor inhibiting HIF (FIH) in the nucleus have
been observed in 125 BRCA-associated breast cancers [41].
PHD3 and FIH are responsible for the HIF-1α degradation
and modulation observed in BRCA1-mutated breast cancers.
This observation might explain how the BRCA1 tumors
enhance hypoxic drive.
The number of microvessels that are positive for
vasohibin-1 (a negative feedback regulator of angiogenesis)
and vasohibin-1 mRNA levels in 17 breast ductal carcinomas
in situ (DCIS) is signiﬁcantly lower compared to those of
22 invasive ductal carcinomas [42]. This diﬀerence has not
been observed when analyzing CD31. However, the number
of vasohibin-1-positive microvessels and vasohibin-1 mRNA
levels shows signiﬁcant correlations with the Ki-67-labeling
index and a high nuclear and histological grade in DCIS
cases.
Multiple roles of COX-2 in tumor angiogenesis, such
as VEGF production, the promotion of vascular sprouting,
migration, and tube formation, have been well studied
[43]. COX2 expression occurs in malignant cells and under
preneoplastic conditions, such as esophageal dysplasia [44].
In a study of 49 DCIS samples without any invasive com-
ponent, the investigators have shown that VEGF expression
is signiﬁcantly associated with COX-2 expression [45]. This
result is in agreement with a xenograft model in a human
DCIS study that observed that COX2 upregulation in DCIS
xenografts increased VEGF and MMP14 expression [46].4 Journal of Oncology
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Figure 2: Delta-like ligand 4 (DLL4) and its expression in bone marrow-derived cells. The expression level of DLL4 dictates the role of
bone marrow-derived cells in the neovasculature. DLL-4-Notch signaling controls tip cell versus stalk cell fate in endothelial cells and has a
regulatory eﬀect on pericyte formation [66].
4. Antiangiogenic Therapies and Pericytes
One of the main mechanisms of action of antiangiogenic
agents is vascular normalization [47]. These drugs change
the balance of pro- and antiangiogenic factors in the tumor
tissue and ﬁx the delivery system to ensure that oxygen and
therapeutic drugs are eﬀectively distributed to a larger num-
ber of tumor cells. In other words, they help the immature
tumor vasculature mature. One of the well-studied factors
that maintains vascular maturity is the close association
between PCs and ECs [48]. Activated ECs sprout and form
an endothelial tube, which is a lumen with an EC lining.
TheseECsstopproliferatingandsecretePDGFtorecruitPCs
and progenitor PCs (e.g., from bone marrow), which express
PDGF receptors (PDGF-Rs) [49]. Recruited PCs proliferate
and encapsulate these new channels. Newly formed vessels
that are enveloped with PCs mature and stop remodeling
[50]. Pericytes stabilize the neovessels and are crucial for
EC survival by locally releasing VEGF and angiopoietin-
1[ 51] .T h e r a p i e st h a tt a r g e tV E G Fh a v eb e e no b s e r v e dt o
selectively prune ECs that are not covered by PCs [52].
Paracrine EC-PC signaling that is mediated by members of
the PDGF family may account for the relative resistance of
more mature vessels to anti-VEGF therapies [53]. Although
bevacizumab has shown clinical eﬃcacy in the treatment of
several tumor types, no treatment-predictive-markers have
been established in clinics [54].
Hypertension (HTN) has been reported to be a common
event associated with bevacizumab treatment, possibly due
to EC-derived nitric oxide reduction and consecutive vas-
cular smooth muscle constriction, which increases vascular
resistance [55]. In a large meta-analysis, the incidence of
HTNinbevacizumab-treatedcancerpatientswas23.6%with
7.9% of patients with grade 3-4 of HTN [56]. Recent studies
on metastatic colon cancer [57], renal cell carcinoma [58],
lung cancer [59], and breast carcinoma [60] have shown an
association between bevacizumab-related HTN and a better
outcome, which suggests that HTN may be a predictive
factor. An exploratory retrospective analysis of samples from
the AVF2119g phase III trial has shown no progression-
free survival (PFS) beneﬁts from the addition of beva-
cizumab to neoadjuvant capecitabine in metastatic breast
cancer patients and has revealed that subgroups with low
expression of endothelial neuropilin-1 (NRP1), TP, VEGF-
C, or endothelial delta-like ligand 4 (DLL4) showed trends
toward PFS beneﬁts [61]. This result is compatible with
the study on rectal carcinoma showing that bevacizumab
upregulated NRP1 in tumor-associated-macrophages [62].
NRP1 is a co-receptor for VEGF and is expressed on ECs,
tumorcellsandvascularsmoothmusclecells[63].Preclinical
studies have shown that combining bevacizumab treatment
with anti-NRP1B treatment resulted in additive eﬀects to
inhibittumorgrowth[64].DLL4expressiononECsactivates
the Notch signaling pathway, which results in the regulation
of tumor angiogenesis in a VEGF-independent manner [65].
DLL4 is expressed by ECs, EPCs, and bone marrow-derived
α-smooth muscle actin (α-SMA)-positive mural cells (e.g.,
pericytes) (Figure 2)[ 66]. Disruption of DLL4 signaling in
combination with anti-VEGF treatment has shown additive
eﬀects on tumor growth [67]. Compared to 64.5% of DLL4-
negative vessels, 98.7% of DLL4-positive tumor vessels are
surrounded by α-SMA-positive pericytes in bladder cancer
[68].
Monocyte chemoattractant protein-1 (MCP-1) is a pro-
tein that is produced by breast cancer cells and stromal cells
and participates in VEGF-mediated angiogenesis [69]. WeJournal of Oncology 5
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Figure 3: Tumor cell-derived PDGF-B induced pericyte diﬀerentiation. Incorporation of pericytes into newly formed vessels is one of the
keystepstoterminateangiogenesis.StudiesinanimalmodelshaveshownthatPDGF-Bisresponsiblefor(1)diﬀerentiationofpericytesfrom
mesenchymal stem cells through the PDGF-B-NRP-1 signaling pathway (2) increased recruitment and attachment of newly diﬀerentiated
pericytes into newly formed tumor vessels. In addition, Flk1+ cells diﬀerentiate into endothelial cells or pericytes upon stimulation by VEGF
or PDGF-B [72].
have previously shown that MCP-1 alone or in combination
with VEGF is a signiﬁcant prognostic factor in breast cancer
[69]. MCP-1 is a direct gene target for TGF-β in ECs
and mediates the angiogenic eﬀect of TGF-β by promoting
the recruitment of mural cells to ECs [70]. Although the
immunoregulatory role of MCP-1 in breast tumor metastasis
has been shown [71], its involvement in tumor vessel
maturationmightbeanotherfactorinmetastasispromotion.
An in vitro study using mouse embryonic mesenchymal
stem cells has shown that tumor cell-derived PDGF-B plays
an important role in the diﬀerentiation and recruitment of
PCs through NRP1 signaling (Figure 3)[ 72]. Less aggressive
cell lines, such as MCF-7 cells (a noninvasive breast cancer
cell line), have been shown to cause more recruitment and
attachment of PCs to blood vessels compared to aggressive
cell lines, such as MDA-MB-231. Another animal study
has shown that tumor-derived PDGF-BB upregulates the
transcription of stromal derived factor-1α (SDF-1α)i nE C s
[73]. EC-derived SDF-1α forms a chemotactic gradient that
recruits CXCR4+ pericytes and smooth muscle progenitor
cells during cancerous vascular remodeling. Another malig-
nant cell-derived factor involved in the normalization of the
tumor vasculature is PlGF [74]. This growth factor only
binds to VEGFR1, forms a heterodimer with VEGF that
inhibits angiogenesis, and leads to vascular remodeling by
forming pericyte-enriched vascular networks (Figure 4).
The combination of anti-VEGF-R and anti-PDGF-R
antibodies enforces tumor vessel regression by interfering
with PC-mediated EC survival mechanisms [75]. Other
studies have revealed that inhibiting PDGF-R improves
tumor drug uptake in experimental tumor models [76].
Hepatocyte growth factor (HGF), a mesenchymal-derived
protein, is a potent chemokine that regulates the growth and
motility of many cell types, such as vascular smooth muscle
cells [77]. Upon activation by angiopoietin-1, ECs produce
HGF, which in turn leads to the migration of smooth muscle
cells toward ECs [78]. XL880 (foretinib, GSK1363089) and
XL184 (cabozantinib) are small molecule inhibitors that
potently block multiple RTKs including VEGFR and the
receptor of hepatocyte growth factor, c-Met. In a mouse
model of pancreatic islet tumors, treatment with XL880 or
XL184 led to rapid, widespread, and progressive regression
ofthetumorvasculatureandreducedpericytenumbers[79].
5. Quantiﬁcationof Angiogenesis
In clinical routines, the response to antitumor therapies
(chemo- or radiotherapy) is usually assessed by measuring6 Journal of Oncology
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Figure 4: Negative regulation of angiogenesis by the PlGF-VEGFR1-mediated signaling pathway. In PlGF-producing mouse Lewis lung and
human tumors, the tumor vasculature that is induced by PlGF-1 and -2 is covered by pericytes and is less leaky compared to the tumor
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[74].
tumorsize[80].However,strategieswithmorespeciﬁcityare
neededtoprovideinformationabouttumorvitality.Imaging
of angiogenic and antiangiogenic behaviors is an essential
component to evaluate antiangiogenic therapy. Various
quantitative imaging techniques, such as positron emission
tomography (PET) [81], magnetic resonance imaging (MRI)
[82], or X-ray-computed tomography (CT) [83], are being
used to evaluate changes in the tumor vasculature following
the administration of angiogenesis inhibitors. However,
these techniques can only reﬂect the physiological changes
and require further development before they can be accepted
as surrogate endpoints. These techniques require the use of
blood-pool contrasting agents to characterize tissue blood
volume, perfusion, and vessel permeability [84]. Although
smallvesselshavebeenvisualizedusingthesemethodsinani-
mal models [85], their clinical application is limited due to
thelongscanningtimeorexperimentallyconstructedagents.
Therefore, biopsy and histopathological evaluation are cur-
rently the accepted gold standards in clinical trials. MVD
has been a well-studied marker to assess neoangiogenesis in
several malignancies, such as breast carcinoma. Endothelial
cells express diﬀerent cell surface markers as a function
of developmental age [86]. Diﬀerentiated endothelial cell
speciﬁc markers (e.g., CD31 or CD34) are commonly used
for tissue analysis by single immunohistochemical staining
and MVD analysis. A histological examination of 512 breast
cancer samples has shown that stromal PDGF-R expression
signiﬁcantlycorrelateswithlessfavorableclinicopathological
parameters (e.g., histopathological grade, estrogen receptor
negativity, and high HER2 expression) and shorter survival
rates [87].
Although the single immunohistochemical staining
method allows the analysis of morphological aspects of
angiogenesis, such as vessel size, shape, and density, these
criteria might not be suﬃcient to assess vascular function.
Double immunohistochemical staining using an EC marker
Figure 5: Double-immunostaining of pericytes and endothelial
cells in breast cancer. Double immunostaining for CD31 (red) and
α-SMA (brown) is shown. The blue arrow indicates a vessel that is
CD31+/α-SMA+; the red arrowheads indicate vessels that are only
CD31+. Magniﬁcation ×200.
and a PC marker (e.g., α-SMA) can be used to evaluate
the morphology and the maturity of tumor microvessels
by diﬀerentiating between the vessels with or without PCs.
Our studies have shown that this method is easily applicable
to tissue samples from formalin-ﬁxed paraﬃn-embedded
pathological archives (Figure 5). Our studies of predictive
factors and prognostic values of microvessel maturity have
used EC-PC double staining in primary breast cancer
patients and are ongoing in patients who have undergone
neoadjuvantchemotherapy.Webelievethatthisnewmethod
has great potential to evaluate the prognostic and predictive
role of angiogenesis from a new prospective. Brain metas-
tases from nonsmall cell lung carcinomas have a higher
proportion of mature vessels compared to primary tumors
independent of the vascular pattern of the primary tumor
[88]. This discordance between the vascular characteristicsJournal of Oncology 7
of primary and secondary cancers suggests that the maturity
of microvessels in primary tumors should be considered
when assessing angiogenesis as a prognostic or predictive
factor. In another study of a small number of breast cancer
samples (n = 50), blood vessel maturity was assessed
by the positivity of LH39 at the lamina lucida of mature
microvessels [89]. Mature blood vessels are deﬁned by
staining with antibodies to LH39 and CD31, using double
immunohistochemistry, whereas immature blood vessels are
characterized by positive CD31 staining. The vascular matu-
rity index (VMI) is deﬁned as the percentage of the fraction
of mature vessels (LH39-positive)/total number of vessels
(CD31-positive). TP expression but not VEGF expression
is correlated with a low VMI showing intense vascular
remodeling in TP-expressing cancers. TP is highly expressed
in breast cancer cells and inﬂammatory cells in the stroma
[90]. Its antiapoptotic and proangiogenic roles have been
well studied. Therefore, the assessment of vessel maturity
and microvessel count may identify patients who might
beneﬁt more from speciﬁc chemotherapy or antiangiogenic
therapies.
Circulating endothelial cells (CECs) and circulating
progenitor cells (CPCs) are novel surrogate markers of
vascular disruption and repair in cancer [91]. In a study
of 160 breast cancer patients, CECs are signiﬁcantly higher
in the poor prognostic group based on the Nottingham
Prognostic Index (NPI), whereas CPCs are lower in the
poor prognosis group [92]. Although vascular invasion and
tumor size are independently associated with CECs, Her-2
status positively predicts CPCs. Circulating endothelial cell
analysis in 46 advanced breast cancer patients treated with
metronomic cyclophosphamide, capecitabine, and beva-
cizumab demonstrates that a high level of CECs indicates
an active vascular turnover and predicts a prolonged clinical
beneﬁt for treatment, whereas low CEC counts are evident
during tumor progression [93]. Decreased levels of CECs
are accompanied by increased levels of VEGF-A and basic
ﬁbroblast growth factor, which suggests a switch toward
ad i ﬀerent type of cancer vascularization. High levels of
CECs, which indicate active vascular remodeling, are shown
to be associated with therapeutic responses. However, low
CEC counts in cases of tumor progression might indicate a
more stable microvasculature in these tumors (i.e., mature
microvessels).
6. Conclusion
Combining diﬀerent chemotherapeutic agents and angio-
genic inhibitors normalizes the tumor vasculature, and the
essential role of PCs in microvessel maturity and the con-
comitant histological evaluation of EC-PC interactions, and
tumor microvessel morphology seems to be inevitable. In
addition, the inﬂuence of lymphangiogenesis and EC inter-
actions with tumor cells that express angiogenic receptors
should also be investigated. Many new angiogenic inhibitors
target pathways that are involved in the recruitment of
pericytes to tumor microvessels. Therefore, it is essential
to assess PCs in parallel with ECs when studying the
tumor vasculature. This evaluation, which can be performed
in a diagnostic pathology laboratory, can be used as a
decision-making tool to select patients who might beneﬁt
from antiangiogenic therapies.
Abbreviations
EC: Endothelial cell
PC: Pericyte
VEGF: Vascular endothelial growth factor
PDGF: Platelet-derived growth factor
HIF: Hypoxia-inducible factor
ER: Estrogen receptor
PgR: Progesterone receptor
HER-2: Human epidermal growth factor receptor-2
TNBC: Triple-negative breast cancer.
Acknowledgments
The authors thank Hironobu Sasano M. D., Ph. D., of the
Pathology Department at Tohoku University in Japan for his
discussions and sincere support for conducting this study.
They also thank Takayuki Ueno M. D., Ph. D., of the Breast
Surgery Department at Kyoto University in Japan for his
kind suggestions and support. This study was funded by
research grants from Japan’s Ministry of Health, Labor and
Welfare (the study of the development of the diagnostic
criteria of photoacoustic mammography and broadband
PAT probes was led by Masakazu Toi, H21-TRANS-IPPAN-
010). E. Fakhrejahani was supported in part by the Japanese
Association for the Advancement of Medical Equipment
research fellowship.
References
[1] P. Carmeliet, “Angiogenesis in life, disease and medicine,”
Nature, vol. 438, no. 7070, pp. 932–936, 2005.
[2] P. Carmeliet and R. K. Jain, “Angiogenesis in cancer and other
diseases,” Nature, vol. 407, no. 6801, pp. 249–257, 2000.
[3] J. Folkman, “Tumor angiogenesis: therapeutic implications,”
The New England Journal of Medicine, vol. 285, no. 21, pp.
1182–1186, 1971.
[4] R. L. Engerman, D. Pfaﬀenbach, and M. D. Davis, “Cell
turnover of capillaries,” Laboratory Investigation, vol. 17, no.
6, pp. 738–743, 1967.
[5] D. Hanahan and J. Folkman, “Patterns and emerging mech-
anisms of the angiogenic switch during tumorigenesis,” Cell,
vol. 86, no. 3, pp. 353–364, 1996.
[6] T. Asahara, H. Masuda, T. Takahashi et al., “Bone marrow
origin of endothelial progenitor cells responsible for postnatal
vasculogenesis in physiological and pathological neovascular-
ization,”CirculationResearch,vol.85,no.3,pp.221–228,1999.
[7] D. Marm´ e and N. Fusenig, Tumor Angiogenesis: Basic Mecha-
nisms and Cancer Therapy, Spinger, Berlin, Germany, 2007.
[8] Z. Zhang, K. G. Neiva, M. W. Lingen, L. M. Ellis, and J. E. N¨ or,
“VEGF-dependent tumor angiogenesis requires inverse and
reciprocal regulation of VEGFR1 and VEGFR2,” Cell Death
and Diﬀerentiation, vol. 17, no. 3, pp. 499–512, 2010.
[9] A. Raza, M. J. Franklin, and A. Z. Dudek, “Pericytes and
vessel maturation during tumor angiogenesis and metastasis,”8 Journal of Oncology
American Journal of Hematology, vol. 85, no. 8, pp. 593–598,
2010.
[10] R. Kalluri, “Basement membranes: structure, assembly and
role in tumour angiogenesis,” Nature Reviews Cancer, vol. 3,
no. 6, pp. 422–433, 2003.
[11] S. B. Fox, K. C. Gatter, R. Bicknell et al., “Relationship of
endothelial cell proliferation to tumor vascularity in human
breast cancer,” Cancer Research, vol. 53, no. 18, pp. 4161–4163,
1993.
[12] S. Toﬀoli, A. Roegiers, O. Feron et al., “Intermittent hypoxia
is an angiogenic inducer for endothelial cells: role of HIF-1,”
Angiogenesis, vol. 12, no. 1, pp. 47–67, 2009.
[13] R. J. Gillies, P. A. Schornack, T. W. Secomb, and N. Raghu-
nand, “Causes and eﬀects of heterogeneous perfusion in
tumors,” Neoplasia, vol. 1, no. 3, pp. 197–207, 1999.
[14] S. B. Fox, D. G. Generali, and A. L. Harris, “Breast tumour
angiogenesis,” Breast Cancer Research, vol. 9, no. 6, p. 216,
2007.
[ 1 5 ]K .E n g e l s ,S .B .F o x ,R .M .W h i t e h o u s e ,K .C .G a t t e r ,a n dA .
L. Harris, “Distinct angiogenic patterns are associated with
high-grade in situ ductal carcinomas of the breast,” Journal of
Pathology, vol. 181, no. 2, pp. 207–212, 1997.
[16] S. B. Fox, R. D. Leek, J. Bliss et al., “Association of tumor
angiogenesis with bone marrow micrometastases in breast
cancer patients,” Journal of the National Cancer Institute, vol.
89, no. 14, pp. 1044–1049, 1997.
[17] D. M. Barnes, R. R. Millis, C. E. Gillett et al., “The interaction
of oestrogen receptor status and pathological features with
adjuvant treatment in relation to survival in patients with
operable breast cancer: a retrospective study of 2660 patients,”
Endocrine-Related Cancer, vol. 11, no. 1, pp. 85–96, 2004.
[18] D. J. Slamon, B. Leyland-Jones, S. Shak et al., “Use of
chemotherapy plus a monoclonal antibody against her2 for
metastatic breast cancer that overexpresses HER2,” The New
England Journal of Medicine, vol. 344, no. 11, pp. 783–792,
2001.
[19] R. Callahan and S. Hurvitz, “Human epidermal growth factor
receptor-2-positive breast cancer: current management of
early, advanced, and recurrent disease,” Current Opinion in
Obstetrics and Gynecology, vol. 23, no. 1, pp. 37–43, 2011.
[20] W.D.Foulkes,I.E.Smith,andJ.S.Reis-Filho,“Triple-negative
breast cancer,” The New England Journal of Medicine, vol. 363,
no. 20, pp. 1938–1948, 2010.
[21] C. M. Perou, T. Sørile, M. B. Eisen et al., “Molecular portraits
ofhumanbreasttumours,”Nature,vol.406,no.6797,pp.747–
752, 2000.
[22] A. Prat, J. S. Parker, O. Karginova et al., “Phenotypic and
molecular characterization of the claudin-low intrinsic sub-
type of breast cancer,” Breast Cancer Research, vol. 12, no. 5,
article no. R68, 2010.
[23] L. A. Carey, C. M. Perou, C. A. Livasy et al., “Race, breast
cancer subtypes, and survival in the Carolina Breast Cancer
Study,” Journal of the American Medical Association, vol. 295,
no. 21, pp. 2492–2502, 2006.
[24] Y. Liu, R. M. Tamimi, L. C. Collins et al., “The association
betweenvascularendothelialgrowthfactorexpressionininva-
sive breast cancer and survival varies with intrinsic subtypes
and use of adjuvant systemic therapy: results from the Nurses’
Health Study,” Breast Cancer Research and Treatment, vol. 129,
no. 1, pp. 175–184, 2011.
[25] R. Sarmiento, M. R. D’Andrea, F. Cacciamani, F. Salerno,
and G. Gasparini, “Antiangiogenic therapies in breast cancer,”
Current Opinion in Investigational Drugs, vol. 10, no. 12, pp.
1334–1345, 2009.
[26] A. Valachis, N. P. Polyzos, N. A. Patsopoulos, V. Georgoulias,
D. Mavroudis, and D. Mauri, “Bevacizumab in metastatic
breast cancer: a meta-analysis of randomized controlled
trials,” Breast Cancer Research and Treatment, vol. 122, no. 1,
pp. 1–7, 2010.
[27] L. Ryd´ en, K. Jirstrom, M. Haglund, O. Stal, and M. Fern¨ o,
“Epidermal growth factor receptor and vascular endothelial
growth factor receptor 2 are speciﬁc biomarkers in triple-
negative breast cancer. Results from a controlled randomized
trial with long-term follow-up,” Breast Cancer Research and
Treatment, vol. 120, no. 2, pp. 491–498, 2010.
[28] J. T. Camp, F. Elloumi, E. Roman-Perez et al., “Interactions
with ﬁbroblasts are distinct in Basal-like and luminal breast
cancers,” Molecular Cancer Research, vol. 9, no. 1, pp. 3–13,
2011.
[29] R. A. Mohammed, I. O. Ellis, A. M. Mahmmod et al.,
“Lymphatic and blood vessels in basal and triple-negative
breast cancers: characteristics and prognostic signiﬁcance,”
Modern Pathology, vol. 24, no. 6, pp. 774–785, 2011.
[30] T. Asahara, T. Murohara, A. Sullivan et al., “Isolation of
putativeprogenitorendothelialcellsforangiogenesis,”Science,
vol. 275, no. 5302, pp. 964–967, 1997.
[31] H. Kennecke, R. Yerushalmi, R. Woods et al., “Metastatic
behavior of breast cancer subtypes,” Journal of Clinical Oncol-
ogy, vol. 28, no. 20, pp. 3271–3277, 2010.
[32] R. Harfouche, R. Echavarria, S. A. Rabbani, A. Arakelian,
M. A. Hussein, and S. N. A. Hussain, “Estradiol-dependent
regulation of angiopoietin expression in breast cancer cells,”
Journal of Steroid Biochemistry and Molecular Biology, vol. 123,
no. 1-2, pp. 17–24, 2011.
[33] M. J. Slade, R. Payne, S. Riethdorf et al., “Comparison
of bone marrow, disseminated tumour cells and blood-
circulatingtumourcellsinbreastcancerpatientsafterprimary
treatment,” British Journal of Cancer, vol. 100, no. 1, pp. 160–
166, 2009.
[34] Y.Liang,R.A.Brekken,andS.M.Hyder,“Vascularendothelial
growth factor induces proliferation of breast cancer cells
and inhibits the anti-proliferative activity of anti-hormones,”
Endocrine-Related Cancer, vol. 13, no. 3, pp. 905–919, 2006.
[35] G. Kallergi, H. Markomanolaki, V. Giannoukaraki et al.,
“Hypoxia-induciblefactor-1αandvascularendothelialgrowth
factor expression in circulating tumor cells of breast cancer
patients,”BreastCancerResearch,vol.11,no.6,articleno.R84,
2009.
[ 3 6 ]Z .H u ,C .F a n ,C .L i v a s ye ta l . ,“ Ac o m p a c tV E G Fs i g n a t u r e
associated with distant metastases and poor outcomes,” BMC
Medicine, vol. 7, article no. 9, 2009.
[37] Y. Ito, Y. Oike, K. Yasunaga et al., “Inhibition of angiogenesis
and vascular leakiness by angiopoietin-related protein 4,”
Cancer Research, vol. 63, no. 20, pp. 6651–6657, 2003.
[38] K. L. Fritz-Six, W. P. Dunworth, M. Li, and K. M. Caron,
“Adrenomedullin signaling is necessary for murine lymphatic
vascular development,” Journal of Clinical Investigation, vol.
118, no. 1, pp. 40–50, 2008.
[39] S. A. Narod, “BRCA mutations in the management of breast
cancer: the state of the art,” Nature Reviews Clinical Oncology,
vol. 7, no. 12, pp. 702–707, 2010.
[ 4 0 ]P .V a nD e rG r o e p ,A .B o u t e r ,F .H .M e n k o ,E .V a nD e rW a l l ,
and P. J. Van Diest, “High frequency of HIF-1α overexpression
in BRCA1 related breast cancer,” Breast Cancer Research and
Treatment, vol. 111, no. 3, pp. 475–480, 2008.
[41] M. Yan, M. Rayoo, E. A. Takano, H. Thorne, and S. B. Fox,
“BRCA1tumourscorrelatewithaHIF-1αphenotypeandhave
a poor prognosis through modulation of hydroxylase enzymeJournal of Oncology 9
proﬁle expression,” British Journal of Cancer, vol. 101, no. 7,
pp. 1168–1174, 2009.
[42] K. Tamaki, H. Sasano, Y. Maruo et al., “Vasohibin-1 as a
potential predictor of aggressive behavior of ductal carcinoma
in situ of the breast,” Cancer science, vol. 101, no. 4, pp. 1051–
1058, 2010.
[43] S. Gately and W. W. Li, “Multiple roles of COX-2 in tumor
angiogenesis: a target for antiangiogenic therapy,” Seminars in
Oncology, vol. 31, no. 7, pp. 2–11, 2004.
[44] Y. Kumagai, M. Toi, and H. Inoue, “Dynamism of tumour
vasculature in the early phase of cancer progression: outcomes
from oesophageal cancer research,” The Lancet Oncology, vol.
3, no. 10, pp. 604–610, 2002.
[45] G.Perrone,D.Santini,B.Vincenzietal.,“COX-2expressionin
DCIS: correlation with VEGF, HER-2/neu, prognostic molec-
ularmarkersandclinicopathologicalfeatures,”Histopathology,
vol. 46, no. 5, pp. 561–568, 2005.
[ 4 6 ]M .H u ,G .P e l u ﬀo, H. Chen, R. Gelman, S. Schnitt, and K.
Polyak, “Role of COX-2 in epithelial-stromal cell interactions
and progression of ductal carcinoma in situ of the breast,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 106, no. 9, pp. 3372–3377, 2009.
[47] R. K. Jain, “Normalization of tumor vasculature: an emerging
concept in antiangiogenic therapy,” Science, vol. 307, no. 5706,
pp. 58–62, 2005.
[48] L. E. Benjamin, I. Hemo, and E. Keshet, “A plasticity window
for blood vessel remodelling is deﬁned by pericyte coverage of
the preformed endothelial network and is regulated by PDGF-
Ba n dV E G F , ”Development, vol. 125, no. 9, pp. 1591–1598,
1998.
[49] C. Lamagna and G. Bergers, “The bone marrow constitutes a
reservoir of pericyte progenitors,” Journal of Leukocyte Biology,
vol. 80, no. 4, pp. 677–681, 2006.
[50] G. Bergers and S. Song, “The role of pericytes in blood-vessel
formation and maintenance,” Neuro-Oncology, vol. 7, no. 4,
pp. 452–464, 2005.
[51] A. Abramsson, P. Lindblom, and C. Betsholtz, “Endothelial
and nonendothelial sources of PDGF-B regulate pericyte
recruitment and inﬂuence vascular pattern formation in
tumors,” Journal of Clinical Investigation, vol. 112, no. 8, pp.
1142–1151, 2003.
[52] J. Huang, S. Z. Softer, E. S. Kim et al., “Vascular remodeling
marks tumors that recur during chronic suppression of
angiogenesis,” Molecular Cancer Research, vol. 2, no. 1, pp. 36–
42, 2004.
[53] Y. Crawford, I. Kasman, L. Yu et al., “PDGF-C mediates
the angiogenic and tumorigenic properties of ﬁbroblasts
associated with tumors refractory to anti-VEGF treatment,”
Cancer Cell, vol. 15, no. 1, pp. 21–34, 2009.
[54] A.M.JubbandA.L.Harris,“Biomarkerstopredicttheclinical
eﬃcacy of bevacizumab in cancer,” The Lancet Oncology, vol.
11, no. 12, pp. 1172–1183, 2010.
[55] H. F. Dvorak, “Vascular permeability factor/vascular endothe-
lial growth factor: a critical cytokine in tumor angiogenesis
and a potential target for diagnosis and therapy,” Journal of
Clinical Oncology, vol. 20, no. 21, pp. 4368–4380, 2002.
[56] V.Ranpura,B.Pulipati,D.Chu,X.Zhu,andS.Wu,“Increased
risk of high-grade hypertension with bevacizumab in cancer
patients: a Meta-Analysis,” American Journal of Hypertension,
vol. 23, no. 5, pp. 460–468, 2010.
[57] P. ¨ Osterlund, L. M. Soveri, H. Isoniemi, T. Poussa, T. Al-
anko, and P. Bono, “Hypertension and overall survival in
metastatic colorectal cancer patients treated with bevac-
izumab-containing chemotherapy,” British Journal of Cancer,
vol. 104, no. 4, pp. 599–604, 2011.
[58] P. Bono, H. Elfving, T. Utriainen et al., “Hypertension and
clinical beneﬁt of bevacizumab in the treatment of advanced
renal cell carcinoma,” Annals of Oncology,v o l .2 0 ,n o .2 ,p p .
393–394, 2009.
[ 5 9 ]S .E .D a h l b e r g ,A .B .S a n d l e r ,J .R .B r a h m e r ,J .H .S c h i l l e r ,
and D. H. Johnson, “Clinical course of advanced non-small-
cell lung cancer patients experiencing hypertension during
treatment with bevacizumab in combination with carboplatin
and paclitaxel on ECOG 4599,” Journal of Clinical Oncology,
vol. 28, no. 6, pp. 949–954, 2010.
[60] B. P. Schneider, M. Wang, M. Radovich et al., “Association of
vascular endothelial growth factor and vascular endothelial
growth factor receptor-2 genetic polymorphisms with out-
come in a trial of paclitaxel compared with paclitaxel plus
bevacizumab in advanced breast cancer: ECOG 2100,” Journal
of Clinical Oncology, vol. 26, no. 28, pp. 4672–4678, 2008.
[61] A. M. Jubb, K. D. Miller, H. S. Rugo et al., “Impact of
exploratory biomarkers on the treatment eﬀect of beva-
cizumab in metastatic breast cancer,” Clinical Cancer Research,
vol. 17, no. 2, pp. 372–381, 2011.
[62] L. Xu, D. G. Duda, E. Di Tomaso et al., “Direct evidence that
bevacizumab, an anti-VEGF antibody, up-regulates SDF1α,
CXCR4, CXCL6, and neuropilin 1 in tumors from patients
with rectal cancer,” Cancer Research, vol. 69, no. 20, pp. 7905–
7910, 2009.
[ 6 3 ]K .M a r c u s ,M .J o h n s o n ,R .M .A d a me ta l . ,“ T u m o rc e l l -
associatedneuropilin-1andvascularendothelialgrowthfactor
expression as determinants of tumor growth in neuroblas-
toma,” Neuropathology, vol. 25, no. 3, pp. 178–187, 2005.
[64] E. Geretti, L. A. Van Meeteren, A. Shimizu, A. C. Dudley,
L. Claesson-Welsh, and M. Klagsbrun, “A mutated solu-
ble neuropilin-2 B domain antagonizes vascular endothelial
growth factor bioactivity and inhibits tumor progression,”
Molecular Cancer Research, vol. 8, no. 8, pp. 1063–1073, 2010.
[65] C. Real, L. Rem´ edio, F. Caiado et al., “Bone marrow-derived
endothelial progenitors expressing Delta-like 4 (Dll4) regulate
tumor angiogenesis,” PLoS ONE, vol. 6, no. 4, article e18323,
2011.
[66] K. S. Stewart, Z. Zhou, P. Zweidler-McKay, and E. S.
Kleinerman, “Delta-like ligand 4-Notch signaling regulates
bone marrow-derived pericyte/vascular smooth muscle cell
formation,” Blood, vol. 117, no. 2, pp. 719–726, 2011.
[67] J. Ridgway, G. Zhang, Y. Wu et al., “Inhibition of Dll4 sig-
nalling inhibits tumour growth by deregulating angiogenesis,”
Nature, vol. 444, no. 7122, pp. 1083–1087, 2006.
[68] N. S. Patel, M. S. Dobbie, M. Rochester et al., “Up-regulation
of endothelial delta-like 4 expression correlates with vessel
maturation in bladder cancer,” Clinical Cancer Research, vol.
12, no. 16, pp. 4836–4844, 2006.
[69] T. Ueno, M. Toi, H. Saji et al., “Signiﬁcance of macrophage
chemoattractantprotein-1inmacrophagerecruitment,angio-
genesis, and survival in human breast cancer,” Clinical Cancer
Research, vol. 6, no. 8, pp. 3282–3289, 2000.
[70] J. Ma, Q. Wang, T. Fei, J. D. J. Han, and Y. G. Chen, “MCP-1
mediates TGF-β-induced angiogenesis by stimulating vascular
smooth muscle cell migration,” Blood, vol. 109, no. 3, pp. 987–
994, 2007.
[71] B. Z. Qian, J. Li, H. Zhang et al., “CCL2 recruits inﬂammatory
monocytestofacilitatebreast-tumourmetastasis,”Nature,vol.
475, no. 7255, pp. 222–225, 2011.
[72] K. Dhar, G. Dhar, M. Majumder et al., “Tumor cell-derived
PDGF-B potentiates mouse mesenchymal stem cells-pericytes10 Journal of Oncology
transition and recruitment through an interaction with NRP-
1,” Molecular Cancer, vol. 9, article no. 209, 2010.
[73] N. Song, Y. Huang, H. Shi et al., “Overexpression of platelet-
derived growth factor-BB increases tumor pericyte content via
stromal-derived factor-1α/CXCR4 axis,” Cancer Research, vol.
69, no. 15, pp. 6057–6064, 2009.
[74] E. M. Hedlund, K. Hosaka, Z. Zhong, R. Cao, and Y. Cao,
“Malignant cell-derived PlGF promotes normalization and
remodeling of the tumor vasculature,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 106, no. 41, pp. 17505–17510, 2009.
[75] G. Bergers, S. Song, N. Meyer-Morse, E. Bergsland, and D.
Hanahan,“Beneﬁtsoftargetingbothpericytesandendothelial
cells in the tumor vasculature with kinase inhibitors,” Journal
of Clinical Investigation, vol. 111, no. 9, pp. 1287–1295, 2003.
[76] A. ¨ Ostman and C. H. Heldin, “PDGF receptors as targets in
tumor treatment,” Advances in Cancer Research, vol. 97, pp.
247–274, 2007.
[ 7 7 ]H .M a ,T .M .C a l d e r o n ,T .K e s s e l ,A .W .A s h t o n ,a n dJ .W .
Berman, “Mechanisms of hepatocyte growth factor-mediated
vascular smooth muscle cell migration,” Circulation Research,
vol. 93, no. 11, pp. 1066–1073, 2003.
[78] H. Kobayashi, L. M. DeBusk, Y. O. Babichev, D. J. Du-
mont, and P. C. Lin, “Hepatocyte growth factor mediates
angiopoietin-inducedsmoothmusclecellrecruitment,”Blood,
vol. 108, no. 4, pp. 1260–1266, 2006.
[79] W. K. You, B. Sennino, C. W. Williamson et al., “VEGF and
c-Met blockade amplify angiogenesis inhibition in pancreatic
islet cancer,” Cancer Research, vol. 71, no. 14, pp. 4758–4758,
2011.
[80] K. James, E. Eisenhauer, M. Christian et al., “Measuring re-
sponse in solid tumors: unidimensional versus bidimensional
measurement,”JournaloftheNationalCancerInstitute,vol.91,
no. 6, pp. 523–528, 1999.
[81] G. R. Laking and P. M. Price, “Positron emission tomographic
imagingofangiogenesisandvascularfunction,”BritishJournal
of Radiology, vol. 76, no. 1, pp. S50–S59, 2003.
[82] T. Barrett, M. Brechbiel, M. Bernardo, and P. L. Choyke,
“MRI of tumor angiogenesis,” Journal of Magnetic Resonance
Imaging, vol. 26, no. 2, pp. 235–249, 2007.
[83] J. P. B. O’Connor, R. A. D. Carano, A. R. Clamp et al.,
“Quantifying antivascular eﬀects of monoclonal antibodies to
vascular endothelial growth factor: insights from imaging,”
Clinical Cancer Research, vol. 15, no. 21, pp. 6674–6682, 2009.
[84] J. C. Miller, H. H. Pien, D. Sahani, A. G. Sorensen, and J. H.
Thrall, “Imaging angiogenesis: application and potential for
drug development,” Journal of the National Cancer Institute,
vol. 97, no. 3, pp. 172–187, 2005.
[85] J. Juanyin, K. Tracy, L. Zhang et al., “Noninvasive imaging
of the functional eﬀects of anti-VEGF therapy on tumor cell
extravasation and regional blood volume in an experimental
brain metastasis model,” Clinical and Experimental Metastasis,
vol. 26, no. 5, pp. 403–414, 2009.
[86] T. Yokota, K. Oritani, S. Butz et al., “The endothelial antigen
ESAMmarksprimitivehematopoieticprogenitorsthroughout
life in mice,” Blood, vol. 113, no. 13, pp. 2914–2923, 2009.
[87] J.Paulsson,T.Sj¨ oblom,P.Mickeetal.,“Prognosticsigniﬁcance
ofstromalplatelet-derivedgrowthfactorbeta-receptorexpres-
sion in human breast cancer,” American Journal of Pathology,
vol. 175, no. 1, pp. 334–342, 2009.
[88] A. M. Jubb, A. Cesario, M. Ferguson et al., “Vascular
phenotypes in primary non-small cell lung carcinomas and
matched brain metastases,” British Journal of Cancer, vol. 104,
no. 12, pp. 1877–1881, 2011.
[89] S. Kakolyris, A. Giatromanolaki, M. Koukourakis et al.,
“Assessement of vascular maturation in lung and breast
carcinomas using a novel basement membrane component,
LH39,” Anticancer Research, vol. 21, no. 6 B, pp. 4311–4316,
2001.
[90] M. Toi, M. Atiqur Rahman, H. Bando, and L. W. C. Chow,
“Thymidine phosphorylase (platelet-derived endothelial-cell
growth factor) in cancer biology and treatment,” The Lancet
Oncology, vol. 6, no. 3, pp. 158–166, 2005.
[91] F. Bertolini, “Chemotherapy and the tumor microenviron-
ment:thecontributionofcirculating endothelial cells,” Cancer
and Metastasis Reviews, vol. 27, no. 1, pp. 95–101, 2008.
[ 9 2 ]P .K .Y .G o o n ,G .Y .H .L i p ,P .S .S t o n e l a k e ,a n dA .D .
Blann, “Circulating endothelial cells and circulating pro-
genitor cells in breast cancer: relationship to endothelial
damage/dysfunction/apoptosis, clinicopathologic factors, and
the Nottingham prognostic index,” Neoplasia, vol. 11, no. 8,
pp. 771–779, 2009.
[93] A. Calleri, A. Bono, V. Bagnardi et al., “Predictive potential
of angiogenic growth factors and circulating endothelial cells
in breast cancer patients receiving metronomic chemotherapy
plus bevacizumab,” Clinical Cancer Research, vol. 15, no. 24,
pp. 7652–7657, 2009.